News
In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant and clinically meaningful cuts in low ...
The top 10 med-tech stock gainers and losers for the week.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback